StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a research note issued to investors on Saturday morning. The firm issued a sell rating on the basic materials company’s stock.
Separately, HC Wainwright reiterated a buy rating and set a $10.00 price objective on shares of Arcadia Biosciences in a research report on Friday, April 5th.
View Our Latest Research Report on Arcadia Biosciences
Arcadia Biosciences Stock Performance
Institutional Investors Weigh In On Arcadia Biosciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in Arcadia Biosciences during the fourth quarter worth $34,000. Vanguard Group Inc. acquired a new stake in Arcadia Biosciences during the fourth quarter worth $44,000. Jane Street Group LLC increased its stake in Arcadia Biosciences by 215.8% during the first quarter. Jane Street Group LLC now owns 36,458 shares of the basic materials company’s stock worth $51,000 after acquiring an additional 24,913 shares during the last quarter. Millennium Management LLC acquired a new stake in Arcadia Biosciences during the second quarter worth $25,000. Finally, State Street Corp increased its stake in Arcadia Biosciences by 76.7% during the first quarter. State Street Corp now owns 99,300 shares of the basic materials company’s stock worth $139,000 after acquiring an additional 43,100 shares during the last quarter. Institutional investors and hedge funds own 17.73% of the company’s stock.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Featured Articles
- Five stocks we like better than Arcadia Biosciences
- What Do S&P 500 Stocks Tell Investors About the Market?
- Silicon Motion Proves That AI in Motion Stays in Motion
- How to Read Stock Charts for Beginners
- Undervalued UnitedHealth Group Won’t Be For Long
- Learn Technical Analysis Skills to Master the Stock Market
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.